Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company deploys an in silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale